Literature DB >> 2551779

Expression of human HPRT mRNA in brains of mice infected with a recombinant herpes simplex virus-1 vector.

T D Palella1, Y Hidaka, L J Silverman, M Levine, J Glorioso, W N Kelley.   

Abstract

Complete deficiency of the purine salvage enzyme hypoxanthine-guanine phosphoribosyltransferase (HPRT) results in a devastating neurological disease, the Lesch-Nyhan syndrome. This disorder has been identified as a candidate for initial attempts at somatic cell gene therapy. We have previously reported the construction of a recombinant herpes simplex virus type 1 (HSV-1) vector containing human hprt cDNA sequences under the regulatory control of the viral thymidine kinase gene (tk) [Palella et al., Mol. Cell. Biol. 8 (1988) 457-460]. Infection of HPRT- cultured rat neuronal cells with these vectors resulted in transient expression of human hprt. In this paper, we report the expression of human hprt mRNA transcripts in the brains of mice infected in vivo with this vector by direct intracranial inoculation. Human hprt transcripts were distinguished from endogenous mouse transcripts by RNase A mapping using riboprobes transcribed from human hprt cDNA. These initial studies demonstrate the transfer and transcription of a human gene in brain cells by direct in vivo infection with recombinant HSV-1 vectors.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2551779     DOI: 10.1016/0378-1119(89)90258-8

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  14 in total

Review 1.  Gene therapy for Parkinson's disease.

Authors:  P Horellou; J Mallet
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

Review 2.  Herpes simplex viral vectors: late bloomers with big potential.

Authors:  Joseph C Glorioso
Journal:  Hum Gene Ther       Date:  2014-02       Impact factor: 5.695

3.  Adenoviruses encoding HPRT correct biochemical abnormalities of HPRT-deficient cells and allow their survival in negative selection medium.

Authors:  T D Southgate; D Bain; L D Fairbanks; A E Morelli; A T Larregina; H A Simmonds; M G Castro; P R Löwenstein
Journal:  Metab Brain Dis       Date:  1999-12       Impact factor: 3.584

Review 4.  The use of chemogenetics in behavioural neuroscience: receptor variants, targeting approaches and caveats.

Authors:  Erin J Campbell; Nathan J Marchant
Journal:  Br J Pharmacol       Date:  2018-02-26       Impact factor: 8.739

5.  Characterization of the molecular defect in a feline model for type II GM2-gangliosidosis (Sandhoff disease).

Authors:  L L Muldoon; E A Neuwelt; M A Pagel; D L Weiss
Journal:  Am J Pathol       Date:  1994-05       Impact factor: 4.307

Review 6.  HSV as a gene transfer vector for the nervous system.

Authors:  J C Glorioso; M A Bender; W F Goins; D J Fink; N DeLuca
Journal:  Mol Biotechnol       Date:  1995-08       Impact factor: 2.695

Review 7.  Herpes simplex virus vectors for gene therapy.

Authors:  D S Latchman
Journal:  Mol Biotechnol       Date:  1994-10       Impact factor: 2.695

8.  Distinctive roles for 2',5'-oligoadenylate synthetases and double-stranded RNA-dependent protein kinase R in the in vivo antiviral effect of an adenoviral vector expressing murine IFN-beta.

Authors:  Khaldun Al-Khatib; Bryan R G Williams; Robert H Silverman; William Halford; Daniel J J Carr
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

Review 9.  Molecular biology of herpes simplex virus type 1 latency in the nervous system.

Authors:  I Steiner; P G Kennedy
Journal:  Mol Neurobiol       Date:  1993       Impact factor: 5.590

Review 10.  Therapeutic epilepsy research: from pharmacological rationale to focal adenosine augmentation.

Authors:  Detlev Boison; Kerry-Ann Stewart
Journal:  Biochem Pharmacol       Date:  2009-08-12       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.